Amivantamab-in-combination-with-Lazertinib-showed-efficacy-in-NSCLC

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer. The most frequent genetic mutation harboured in lung adenocarcinomas occurs in the epidermal growth factor receptor (EGFR), accounting for 40-55% in Asian patients.

ASCO-2021-Liver-Cancer-Update

ASCO 2021 Liver Cancer Update

The liver cancer trials presented at American Society of Clinical Oncology (ASCO) 2021 were mainly focused on first-line treatments, with a few trials in the neoadjuvant, adjuvant and second-line setting.

Effect-of-prior-therapy-on-BRAF-V600E-mutant-metastatic-colorectal-cancer

Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

An exploratory post-hoc analysis of the BEACON CRC study investigated the overall survival (OS) of encorafenib + cetuximab (doublet) and FOLFIRI (control) according to prior therapies (bevacizumab, oxaliplatin, FOLFOXIRI and anticancer therapy [ACT]) in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

The-emerging-role-of-targeted-therapy-in-advanced-urothelial-carcinoma

The emerging role of targeted therapy in advanced urothelial carcinoma

There is no excerpt because this is a protected post.

Advancing care for advanced renal cell carcinoma

Advancing care for advanced renal cell carcinoma: choosing the optimal therapy for you patients

There is no excerpt because this is a protected post.

Lung-Cancer-Update-April-2021

Lung Cancer Update April 2021

With the World Conference on Lung Cancer (WCLC) 2020 completed last January, several new and clinical relevant phase 2 and phase 3 studies on Lung Cancer have been published. We summarised some key data for you.

Abemaciclib-A-review-of-the-evidence-through-clinical-case

Abemaciclib: A review of the evidence through clinical cases

There is no excerpt because this is a protected post.

Breast-Cancer-Update-2021

Breast cancer update January 2021

With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. [‘mediPr] provides you with an overview.

Osimertinib-approved-as-the-first-adjuvant-treatment-for-early-non-small-cell-lung-cancer

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

Lung cancer is a leading cause of cancer-related death. In East Asian non-small cell lung cancer (NSCLC) patients, epidermal growth factor receptor (EGFR) mutations occur in 40-55% of lung adenocarcinomas.

cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women

Cabotegravir and rilpivirine intramuscular combination safe in women

Women account for a disproportionate percentage of new human immunodeficiency virus (HIV) infections in sub-Saharan Africa, comprising 59% of 18 million new adult HIV infections in 2017.